Taysha Gene Therapies Inc
(NAS:TSHA)
$
2.06
-0.09 (-4.19%)
Market Cap: 413.83 Mil
Enterprise Value: 369.69 Mil
PE Ratio: 0
PB Ratio: 7.09
GF Score: 31/100 - Q1 2024 Taysha Gene Therapies Inc Earnings Call TranscriptMay 14, 2024$2.57 (+7.08%)Earnings
- Q4 2023 Taysha Gene Therapies Inc Earnings Call TranscriptMar 19, 2024$2.25 (+5.63%)Earnings
- Q3 2023 Taysha Gene Therapies Inc Earnings Call TranscriptNov 14, 2023$1.33Earnings
- Q2 2023 Taysha Gene Therapies Inc Earnings Call TranscriptAug 14, 2023$2.13 (+188.23%)Earnings
- Taysha Gene Therapies Inc R&D Day TranscriptJun 28, 2023
- Q1 2023 Taysha Gene Therapies Inc Earnings Call TranscriptMay 11, 2023$0.709 (-5.47%)Earnings
- Q4 2022 Taysha Gene Therapies Inc Earnings Call TranscriptMar 28, 2023$0.652 (-6.19%)Earnings
- Taysha Gene Therapies Inc Corporate Update Call TranscriptJan 31, 2023
- Q3 2022 Taysha Gene Therapies Inc Earnings Call TranscriptNov 08, 2022$2.2 (+10.00%)Earnings
- Taysha Gene Therapies Inc to Discuss Astellas Pharma's Strategic InvestmentCall TranscriptOct 25, 2022
- Q2 2022 Taysha Gene Therapies Inc Earnings Call TranscriptAug 11, 2022$3.95 (-19.06%)Earnings
- Taysha Gene Therapies Inc at JMP Securities Life Sciences Conference TranscriptJun 16, 2022
- Q1 2022 Taysha Gene Therapies Inc Earnings Call TranscriptMay 16, 2022$3.32 (-3.49%)Earnings
- Taysha Gene Therapies Inc at Needham Healthcare Conference (Virtual) TranscriptApr 11, 2022
- Taysha Gene Therapies Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) TranscriptApr 01, 2022
- Q4 2021 Taysha Gene Therapies Inc Earnings Call TranscriptMar 31, 2022$6.52 (+6.02%)Earnings
- Taysha Gene Therapies Inc To Discuss TSHA-120 GAN Program Update Call TranscriptJan 31, 2022
- Taysha Gene Therapies Inc To Discuss TSHA-101 In GM2 Gangliosidosis Program Update Call TranscriptJan 27, 2022
- Taysha Gene Therapies Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Q3 2021 Taysha Gene Therapies Inc Earnings Call TranscriptNov 10, 2021$15.74 (+5.14%)Earnings
- Taysha Gene Therapies Inc at Jefferies Gene Therapy/Editing Summit (Virtual) TranscriptOct 28, 2021
- Taysha Gene Therapies Inc Angelman Syndrome Investor Day TranscriptOct 26, 2021
- Taysha Gene Therapies Inc at Chardan Genetic Medicines Conference (Virtual) TranscriptOct 05, 2021
- Taysha Gene Therapies Inc To Discuss CLN7 Program Acquisition Call TranscriptOct 05, 2021
- Taysha Gene Therapies Inc To Host Virtual Key Opinion Leader (KOL) Webinar On TSHA-102 For Treatment Of Rett Syndrome Call TranscriptSep 22, 2021
- Taysha Gene Therapies Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 09, 2021
- Taysha Gene Therapies Inc To Host CLN1 KOL Webinar TranscriptAug 30, 2021
- Q2 2021 Taysha Gene Therapies Inc Earnings Call TranscriptAug 16, 2021$15.82 (-8.98%)Earnings
- Taysha Gene Therapies Inc To Host Manufacturing Investor Day TranscriptJul 27, 2021
- Taysha Gene Therapies Inc R&D Day 2 TranscriptJun 29, 2021
- Taysha Gene Therapies Inc R&D Day 1 TranscriptJun 28, 2021
- Taysha Gene Therapies Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Taysha Gene Therapies Inc at RBC Capital Markets Global Healthcare Conference (Virtual) TranscriptMay 19, 2021
- Q1 2021 Taysha Gene Therapies Inc Earnings Call TranscriptMay 11, 2021$21 (+2.34%)Earnings
- Taysha Gene Therapies Inc GAN Program Acquisition Call TranscriptApr 12, 2021
- Full Year 2020 Taysha Gene Therapies Inc Earnings Call TranscriptMar 03, 2021$25.21Earnings
Taysha Gene Therapies Inc at JMP Securities Life Sciences Conference Transcript
Jun 16, 2022 / 05:00PM GMT
Release Date Price:
$2.87
(-4.65%)
Silvan Türkcan
JMP Securities LLC - Analyst
My name is Silvan Türkcan; I cover precision medicines here at JMP Securities. It's my pleasure to host Kamran Alam, CFO of Taysha; and Suyash Prasad, Chief Medical Officer of Taysha. Thank you very much for joining us today.
Kamran Alam
Taysha Gene Therapies, Inc. - CFO
Thanks very much. Appreciate it.
Suyash Prasad
Taysha Gene Therapies, Inc. - CMO & Head of Research and Development
Pleasure to be here.
Questions & Answers
Silvan Türkcan;Suyash Prasad
JMP Securities LLC - Analyst;Taysha Gene Therapies, Inc. - CMO
Thanks. So obviously, gene therapies have had a unique set of issues over the last, call it, 12 to 18 months apart from the general biotech market. Could you please tell us about what kind of company are you building in the gene therapy space to weather some of the challenges that other competitors may have had? And what's your focus, and how do you make it work?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)